imipenem
imipenem is a pharmaceutical drug with 19 clinical trials. Currently 1 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 10 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
2
Mid Stage
12
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.3%
10 of 12 finished
16.7%
2 ended early
1
trials recruiting
19
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Evaluation of Innovative Tools in Development of Antibiotics
A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients
Clinical Trials (19)
Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Evaluation of Innovative Tools in Development of Antibiotics
A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Imipenem in Critically Ill Patients
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia
Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
Imipenem Prophylaxis in Patients With Acute Pancreatitis
Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin
Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
All 19 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 19